Compass Therapeutics, Inc. (CMPX)
(Real Time Quote from BATS)
$2.78 USD
-0.13 (-4.47%)
Updated Aug 7, 2025 11:36 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Compass Therapeutics, Inc. has a market cap of $402.40M, which represents its share price of $2.91 multiplied by its outstanding shares number of 138.28M. As a small-cap company, CMPX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CMPX 2.78 -0.13(-4.47%)
Will CMPX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Other News for CMPX
Compass Therapeutics (CMPX) Receives Outperform Rating from Raymond James | CMPX Stock News
Compass Therapeutics resumed with an Outperform at Raymond James
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler
Compass Therapeutics management to meet virtually with Piper Sandler